Press Release Service
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
- Jan. 5, 2023
BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.
Read the PR here.
Tags
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, NHL, (NCT05741359)
Sponsors:
Bioray Laboratories![CMN+](https://d2qa4785ekzzy0.cloudfront.net/fileadmin/templates/crisprmedicine/images/CMN-plus-list.png)
Sponsors:
Bioray Laboratories
![CMN+](https://d2qa4785ekzzy0.cloudfront.net/fileadmin/templates/crisprmedicine/images/CMN-plus-list.png)
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III